ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1464

Lupus Flares More Common in Patients on Dialysis Compared to After Renal Transplant: A Systematic Review and Meta-analysis

Omer Pamuk1, Ansaam Daoud2, Loai Dweik3, Niraj Desai4 and sarfaraz Hasni5, 1University Hospitals Cleveland Medical Center, Cleveland, OH, 2University Hospitals, Case Western Reserve University, Akron, OH, 3Cleveland Clinic Akron General, Akron, OH, 4Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, OH, 5Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD

Meeting: ACR Convergence 2023

Keywords: Lupus nephritis, meta-analysis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: End-stage renal disease (ESRD) may develop in up to 20% of patients with lupus nephritis (LN). The SLE disease activity generally declines after the development of ESRD and renal transplantation (RT). However, several studies reported SLE flares could occur after ESRD or RT. In this study, we performed a systematic literature review and meta-analysis to assess the frequency of SLE flares, in patients with ESRD or after RT.

Methods: We used PubMed, Web of Science, and Cochrane Library to search the literature from 1973 to 2023. PRISMA 2020 guidelines and checklist were used to conduct the meta-analysis. Studies investigating frequency of lupus flare in patients after renal replacement therapy (RRT) were included in the analysis. If the information was available, SLE flares were recorded separately for different RRT modalities such as hemodialysis (HD), peritoneal dialysis (PD), and RT. ACR 1997 revised classification criteria was utilized to ascertain SLE diagnosis. We excluded studies that did not mention lupus flares after the development of ESRD or RT. Two authors (O.N.P., A.D.) independently reviewed all articles and evaluated the data for consistency between the abstracts and tables to avoid bias. A forest plot was used to compare odds ratios (95% CI) of SLE flares after ESRD or RT. Study heterogeneity was assessed using I2. All analyses were performed using the R Statistical Software meta package (v4.2.1; R Core Team 2022).

Results: Our literature review revealed 583 relevant articles, 487 were deemed unsuitable by title or abstract. We reviewed the full text of remaining 96 articles and 69 fulfilled study entry criteria. Twenty-eight studies (862 SLE patients) evaluated clinical SLE disease flares after RRT (HD and PD). Overall 30% of patients with ESRD had at least one flare after RRT (Figure 1). Seven studies (307 SLE patients) compared SLE disease flares after PD or HD initiation. The frequency of SLE flares was similar in both PD (25.6%) and HD (25.3%) (OR: 1.05, 95% CI: 0.57-1.94, p=0.88). Clinical SLE disease flares were evaluated in 5 studies after RT (91 patients). 14.3% of patients had at least one clinical SLE flare (95%CI: 8.5-23.1%). Four studies (204 SLE patients) compared lupus flares in SLE patients with PD/HD or RT. Flare risk was significantly higher in PD/HD group when compared to RT (OR: 4.36, 95%CI: 1.66-11.47, p=0.0028) (Figure 2). Twenty-nine studies (7890 SLE patients with RT) analyzed the recurrence of the LN after RT. LN had been diagnosed in 3.4% of patients (95%CI: 3-3.8%) (Figure 3).

Conclusion: Our meta-analysis showed lupus flares can still occur in up to 30%of patients with ESRD on RRT. The risk of flare is increased in patients on dialysis as compared to after RT. The flare risk is similar in patients on either HD or PD. A small percentage of SLE patients get recurrence of LN even after transplant.

Supporting image 1

Figure 1. The frequency of SLE flares after renal replacement therapy.

Supporting image 2

The comparison of lupus disease flares in kidney transplantation and peritoneal dialysis (PD)/hemodialysis (HD) groups

Supporting image 3

Figure 3. The frequency of lupus nephritis flares after the Renal Transplant.


Disclosures: O. Pamuk: None; A. Daoud: None; L. Dweik: None; N. Desai: None; s. Hasni: AstraZeneca, 5.

To cite this abstract in AMA style:

Pamuk O, Daoud A, Dweik L, Desai N, Hasni s. Lupus Flares More Common in Patients on Dialysis Compared to After Renal Transplant: A Systematic Review and Meta-analysis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/lupus-flares-more-common-in-patients-on-dialysis-compared-to-after-renal-transplant-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-flares-more-common-in-patients-on-dialysis-compared-to-after-renal-transplant-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology